Press "Enter" to skip to content

PharmaCyte Biotech Announces Listing Date to NASDAQ

PharmaCyte Biotech Inc., a biotechnology company focused on developing cancer and diabetes cellular therapies using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that its common stock will begin trading on The Nasdaq Capital Market on August 10, 2021, under the symbol “PMCB.” The pricing of the Company’s previously announced underwritten public offering was also announced.

The offering includes 3,529,412 shares of common stock as well as warrants to purchase up to 3,529,412 shares of common stock. Each share of common stock is sold with one warrant to purchase one share of common stock at a combined public offering price of $4.25 per share of common stock and accompanying warrant, less underwriting discounts and commissions.The warrants have a $4.25 per share exercise price, are immediately exercisable, and will expire five years from the date of issuance.

Before deducting underwriting discounts and commissions, as well as other projected offering expenses, PharmaCyte Biotech anticipates to earn gross proceeds of about $15 million from the underwritten public offering. The sole book-running manager for the offering is H.C. Wainwright.PharmaCyte has also given the underwriter a 30-day option to buy up to an additional 529,411 shares of common stock and/or warrants to buy up to an additional 529,411 shares of common stock at the public offering price, less underwriting discounts and fees. PharmaCyte is selling all of the securities offered in the offering. The offering is expected to conclude on or around August 12, 2021, assuming all customary closing conditions are met.

PharmaCyte is offering the securities indicated above pursuant to a shelf registration statement on Form S3 that was previously filed with and later declared valid by the US Securities and Exchange Commission. Only a prospectus, including a prospectus supplement that is part of the effective registration statement may be used to sell the securities. The SEC has filed a preliminary prospectus supplement and supporting base prospectus pertaining to the offering.

Be First to Comment

Leave a Reply

Your email address will not be published. Required fields are marked *